Morphine-3-glucuronide causes antinociceptive cross-tolerance to morphine and increases spinal substance P expression. 2020

Kim J Blomqvist, and Hanna Viisanen, and Fredrik H G Ahlström, and Viljami Jokinen, and Yulia A Sidorova, and Ilida Suleymanova, and Pekka V Rauhala, and Eija A Kalso, and Tuomas O Lilius
Department of Pharmacology, Faculty of Medicine, Haartmaninkatu 8 (Biomedicum 1), 00014, University of Helsinki, Finland; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Tukholmankatu 8C, FI-00290, Helsinki, Finland.

Morphine-3-glucuronide (M3G), the main metabolite of morphine, has been implicated in the development of tolerance and of opioid-induced hyperalgesia, both limiting the analgesic use of morphine. We evaluated the acute and chronic effects of M3G and morphine as well as development of antinociceptive cross-tolerance between morphine and M3G after intrathecal administration and assessed the expression of pain-associated neurotransmitter substance P in the spinal cord. Sprague-Dawley rats received intrathecal M3G or morphine twice daily for 6 days. Nociception and tactile allodynia were measured with von Frey filaments after acute and chronic treatments. Substance P levels in the dorsal horn of the spinal cord were determined by immunohistochemistry after 4-day treatments. Acute morphine caused antinociception as expected, whereas acute M3G caused tactile allodynia, as did both chronic M3G and morphine. Chronic M3G also induced antinociceptive cross-tolerance to morphine. M3G and morphine increased substance P levels similarly in the nociceptive laminae of the spinal cord. This study shows that chronic intrathecal M3G sensitises animals to mechanical stimulation and elevates substance P levels in the nociceptive laminae of the spinal cord. Chronic M3G also induces antinociceptive cross-tolerance to morphine. Thus, chronic M3G exposure might contribute to morphine-induced tolerance and opioid-induced hyperalgesia.

UI MeSH Term Description Entries
D007278 Injections, Spinal Introduction of therapeutic agents into the spinal region using a needle and syringe. Injections, Intraspinal,Injections, Intrathecal,Intraspinal Injections,Intrathecal Injections,Spinal Injections,Injection, Intraspinal,Injection, Intrathecal,Injection, Spinal,Intraspinal Injection,Intrathecal Injection,Spinal Injection
D008297 Male Males
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D009022 Morphine Derivatives Analogs or derivatives of morphine. Morphines
D010147 Pain Measurement Scales, questionnaires, tests, and other methods used to assess pain severity and duration in patients or experimental animals to aid in diagnosis, therapy, and physiological studies. Analgesia Tests,Analogue Pain Scale,Formalin Test,McGill Pain Questionnaire,Nociception Tests,Pain Assessment,Pain Intensity,Pain Severity,Tourniquet Pain Test,Visual Analogue Pain Scale,Analog Pain Scale,Assessment, Pain,McGill Pain Scale,Visual Analog Pain Scale,Analgesia Test,Analog Pain Scales,Analogue Pain Scales,Formalin Tests,Intensity, Pain,Measurement, Pain,Nociception Test,Pain Assessments,Pain Intensities,Pain Measurements,Pain Questionnaire, McGill,Pain Scale, Analog,Pain Scale, Analogue,Pain Scale, McGill,Pain Severities,Pain Test, Tourniquet,Questionnaire, McGill Pain,Scale, Analog Pain,Scale, Analogue Pain,Scale, McGill Pain,Severity, Pain,Test, Analgesia,Test, Formalin,Test, Nociception,Test, Tourniquet Pain,Tests, Nociception,Tourniquet Pain Tests
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006930 Hyperalgesia An increased sensation of pain or discomfort produced by minimally noxious stimuli due to damage to soft tissue containing NOCICEPTORS or injury to a peripheral nerve. Hyperalgesia, Tactile,Hyperalgesia, Thermal,Hyperalgia,Hyperalgia, Mechanical,Hyperalgia, Primary,Hyperalgia, Secondary,Allodynia,Allodynia, Mechanical,Allodynia, Tactile,Allodynia, Thermal,Hyperalgesia, Mechanical,Hyperalgesia, Primary,Hyperalgesia, Secondary,Hyperalgesic Sensations,Mechanical Allodynia,Mechanical Hyperalgesia,Tactile Allodynia,Thermal Allodynia,Allodynias,Hyperalgesias,Hyperalgesias, Thermal,Hyperalgesic Sensation,Mechanical Hyperalgia,Mechanical Hyperalgias,Primary Hyperalgia,Primary Hyperalgias,Secondary Hyperalgia,Secondary Hyperalgias,Sensation, Hyperalgesic,Sensations, Hyperalgesic,Thermal Hyperalgesia

Related Publications

Kim J Blomqvist, and Hanna Viisanen, and Fredrik H G Ahlström, and Viljami Jokinen, and Yulia A Sidorova, and Ilida Suleymanova, and Pekka V Rauhala, and Eija A Kalso, and Tuomas O Lilius
January 1997, European journal of pain (London, England),
Kim J Blomqvist, and Hanna Viisanen, and Fredrik H G Ahlström, and Viljami Jokinen, and Yulia A Sidorova, and Ilida Suleymanova, and Pekka V Rauhala, and Eija A Kalso, and Tuomas O Lilius
January 1991, European journal of pharmacology,
Kim J Blomqvist, and Hanna Viisanen, and Fredrik H G Ahlström, and Viljami Jokinen, and Yulia A Sidorova, and Ilida Suleymanova, and Pekka V Rauhala, and Eija A Kalso, and Tuomas O Lilius
July 1984, Neuropharmacology,
Kim J Blomqvist, and Hanna Viisanen, and Fredrik H G Ahlström, and Viljami Jokinen, and Yulia A Sidorova, and Ilida Suleymanova, and Pekka V Rauhala, and Eija A Kalso, and Tuomas O Lilius
September 2009, Neuroscience letters,
Kim J Blomqvist, and Hanna Viisanen, and Fredrik H G Ahlström, and Viljami Jokinen, and Yulia A Sidorova, and Ilida Suleymanova, and Pekka V Rauhala, and Eija A Kalso, and Tuomas O Lilius
July 1995, Pain,
Kim J Blomqvist, and Hanna Viisanen, and Fredrik H G Ahlström, and Viljami Jokinen, and Yulia A Sidorova, and Ilida Suleymanova, and Pekka V Rauhala, and Eija A Kalso, and Tuomas O Lilius
March 1989, Brain research,
Kim J Blomqvist, and Hanna Viisanen, and Fredrik H G Ahlström, and Viljami Jokinen, and Yulia A Sidorova, and Ilida Suleymanova, and Pekka V Rauhala, and Eija A Kalso, and Tuomas O Lilius
July 1981, Neuropharmacology,
Kim J Blomqvist, and Hanna Viisanen, and Fredrik H G Ahlström, and Viljami Jokinen, and Yulia A Sidorova, and Ilida Suleymanova, and Pekka V Rauhala, and Eija A Kalso, and Tuomas O Lilius
April 1993, Proceedings of the National Academy of Sciences of the United States of America,
Kim J Blomqvist, and Hanna Viisanen, and Fredrik H G Ahlström, and Viljami Jokinen, and Yulia A Sidorova, and Ilida Suleymanova, and Pekka V Rauhala, and Eija A Kalso, and Tuomas O Lilius
January 1985, Neurobehavioral toxicology and teratology,
Kim J Blomqvist, and Hanna Viisanen, and Fredrik H G Ahlström, and Viljami Jokinen, and Yulia A Sidorova, and Ilida Suleymanova, and Pekka V Rauhala, and Eija A Kalso, and Tuomas O Lilius
April 1997, Pain,
Copied contents to your clipboard!